<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82395">
  <stage>Registered</stage>
  <submitdate>19/11/2007</submitdate>
  <approvaldate>8/02/2008</approvaldate>
  <actrnumber>ACTRN12608000071325</actrnumber>
  <trial_identification>
    <studytitle>Before and after clinical trial of Neourotec on patient with fibromyalgia</studytitle>
    <scientifictitle>Before &amp; after clinical trial of Neurotec's (a pharmasutical drug) on reducing pain in patients with fibromyalgia</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Fibromyalgic disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Neurotec administered orally, one capsules containing 100mg of effective substance every 12 hours for 8 weeks. Totally 112 capsule will consume with volunteers during 56 days. Subjects evaluate on bi-weekly basis during treatment and also 4 &amp; 8 weeks after treatment.</interventions>
    <comparator>self control</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain Assessment against Visual Analogus Scale</outcome>
      <timepoint>at baseline and at 2, 4, 6, and 8 weeks after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Psychological examination (interview) based on the Diagnostic and Statistical Manual of Mental Disorders version 4 (DSM-IV)</outcome>
      <timepoint>at baseline and at 2, 4, 6, and 8 weeks after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastrointestinal examination</outcome>
      <timepoint>at baseline and at 2, 4, 6, and 8 weeks after intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Fibromyalgic disorder symptoms based on USA Rheumatologic association' criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Nonvolunteers
Hypothyroidism
Rheumatologic disorders
Psychotic disorders
Sever Congestive Heart Failer (CHF)
Sever and chronic ischemic heart disorder with pulsless limb
Sever disease: Cancers, Vasculitis
Alcohol or Drug abuse
Chronic renal failer
Dialysis
Sever hepatic failer
Treatment with corticosteroids
Immuno suppressive therapy
Radiotherapy
Chemotherapy
Any hypersentivity disorder
Electrolytes disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Patient with fibromyalgic symptoms examine with neurologist and rheumatoligist separately and include based on US Rheumatologic association criteria</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Rhuematologic Ward</primarysponsorname>
    <primarysponsoraddress>Tehran University of Medical Sciences
Kargar Ave,Shariati Hospital
Rhuematologic Ward
Tehran ,Iran</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Parsroos Co.</fundingname>
      <fundingaddress>No. 21, 9th Alley, North Falamak St., Shahrak-e-Gharb, Tehran 14678-76744</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Rhuematologic Research Center</sponsorname>
      <sponsoraddress>Tehran University of Medical Sciences
Rhuematologic Research Center
Kargar Ave,Shariati Hospital
Tehran ,Iran</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evaluate the safety and efficacy effect of Neurotec on fibromyalgia and its signs and symptoms. It is hypothesized that Neurotec is a safe drug and effective in reducing the pain, GI disorder, sleep disorder and treatment of Fibromialgia.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Digestive Disease Research Center, Ethical Committee</ethicname>
      <ethicaddress>Tehran University of Medical Sciences
Digestive Disease Research Center
Kargar Ave,Shariati Hospital
Tehran ,Iran</ethicaddress>
      <ethicapprovaldate>13/09/2007</ethicapprovaldate>
      <hrec>FWA00001331</hrec>
      <ethicsubmitdate>14/07/2007</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Digestive Disease Research Center, Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Ahmadreza Jamshidi</name>
      <address>Tehran University of Medical Sciences
Rhuematologic Research Center
Kargar Ave,Shariati Hospital
Tehran ,Iran</address>
      <phone>0098-912-1259701</phone>
      <fax>+ 98 21 8802 6956</fax>
      <email>jamshida@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Ali Dehghan</name>
      <address>Tehran University of Medical Sciences
Rhuematologic Research Center
Kargar Ave,Shariati Hospital
Tehran ,Iran</address>
      <phone>0098-912-5146500</phone>
      <fax>+ 98 21 8802 6956</fax>
      <email>alidehghan@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Afshin Aslani</name>
      <address>Tehran University of Medical Sciences
Digestive Disease Research Center
Kargar Ave,Shariati Hospital
14155-5914,Tehran ,Iran</address>
      <phone>0098-912-327-3541</phone>
      <fax />
      <email>afshin@tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>